Apollon Formularies (AQSE:APOL) Net Income Including Noncontrolling Interests : £-0.76 Mil (TTM As of Jun. 2023)

View and export this data going back to . Start your Free Trial

What is Apollon Formularies Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Apollon Formularies's Net Income Including Noncontrolling Interests for the six months ended in Jun. 2023 was £-0.76 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.76 Mil.

Apollon Formularies Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Apollon Formularies's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies Net Income Including Noncontrolling Interests Chart

Apollon Formularies Annual Data

Trend

Jun10

Jun11

Dec12

Dec13

Dec14

Dec17

Dec18

Dec19

Dec20

Dec21

Net Income Including Noncontrolling Interests

Get a 7-Day Free Trial

-0.04

-0.32

-2.18

-0.50

-2.53

Apollon Formularies Semi-Annual Data
	Jun11	Jun12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Jun23
Net Income Including Noncontrolling Interests	Get a 7-Day Free Trial											-0.11	-1.70	-0.84	-0.21	-0.76

Apollon Formularies Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.76 Mil.

Apollon Formularies Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Apollon Formularies (AQSE:APOL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » Net Income Including Noncontrolling Interests

Comparable Companies

Traded in Other Exchanges

N/A

Address

6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS

Website

https://www.apollon.org.uk

Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.